427 related articles for article (PubMed ID: 21507517)
1. Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Fujita Y; Yoshioka N; Abe R; Murata J; Hoshina D; Mae H; Shimizu H
J Am Acad Dermatol; 2011 Jul; 65(1):65-8. PubMed ID: 21507517
[TBL] [Abstract][Full Text] [Related]
2. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment.
Murata J; Abe R; Shimizu H
J Allergy Clin Immunol; 2008 Nov; 122(5):992-1000. PubMed ID: 18692887
[TBL] [Abstract][Full Text] [Related]
3. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features.
Cho YT; Lin JW; Chen YC; Chang CY; Hsiao CH; Chung WH; Chu CY
J Am Acad Dermatol; 2014 Mar; 70(3):539-48. PubMed ID: 24388722
[TBL] [Abstract][Full Text] [Related]
4. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.
Sane SP; Bhatt AD
J Assoc Physicians India; 2000 Oct; 48(10):999-1003. PubMed ID: 11200928
[TBL] [Abstract][Full Text] [Related]
5. [Stevens-Johnson syndrome and toxic epidermal necrolysis--updates and innovations].
Halevy S
Harefuah; 2010 Mar; 149(3):186-90, 193. PubMed ID: 20684173
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M
Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936
[TBL] [Abstract][Full Text] [Related]
7. Stevens-Johnson syndrome and toxic epidermal necrolysis.
Harr T; French LE
Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
[TBL] [Abstract][Full Text] [Related]
8. [Stevens-Johnson syndrome and toxic epidermal necrolysis in Togo: the role of self-medication].
Saka B; Kombaté K; Egbohou P; Mouhari-Toure A; Akakpo S; Boukari T; Tchangaï-Walla K; Pitché P
Ann Dermatol Venereol; 2012 Jun; 139(6-7):486-7. PubMed ID: 22721483
[No Abstract] [Full Text] [Related]
9. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.
Teraki Y; Shibuya M; Izaki S
Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350
[TBL] [Abstract][Full Text] [Related]
10. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
[TBL] [Abstract][Full Text] [Related]
11. [Toxic epidermal necrolysis and Stevens-Johnson syndrome].
Roujeau JC
Rev Prat; 2007 Jun; 57(11):1165-70. PubMed ID: 17691257
[TBL] [Abstract][Full Text] [Related]
12. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
[TBL] [Abstract][Full Text] [Related]
13. European Dermatology Forum: skin diseases in Europe. Skin diseases with a high public health impact: toxic epidermal necrolysis and Stevens-Johnson syndrome.
Fritsch P
Eur J Dermatol; 2008; 18(2):216-7. PubMed ID: 18424404
[No Abstract] [Full Text] [Related]
14. High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome.
Nakajima S; Watanabe H; Tohyama M; Sugita K; Iijima M; Hashimoto K; Tokura Y; Nishimura Y; Doi H; Tanioka M; Miyachi Y; Kabashima K
Arch Dermatol; 2011 Sep; 147(9):1110-2. PubMed ID: 21931056
[No Abstract] [Full Text] [Related]
15. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Med Clin North Am; 2010 Jul; 94(4):727-42, x. PubMed ID: 20609860
[TBL] [Abstract][Full Text] [Related]
16. The Role of IL-13, IL-15 and Granulysin in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
Sadek M; Iqbal O; Siddiqui F; Till S; Mazariegos M; Campbell E; Mudaliar K; Speiser J; Bontekoe E; Kouta A; Farooqui A; Daravath B; Qneibi D; Sadek R; Hoppensteadt D; Fareed J; Bouchard C
Clin Appl Thromb Hemost; 2021; 27():1076029620950831. PubMed ID: 33560872
[TBL] [Abstract][Full Text] [Related]
17. Systemic lupus erythematosus presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: a report of three cases.
Lee HY; Tey HL; Pang SM; Thirumoorthy T
Lupus; 2011 May; 20(6):647-52. PubMed ID: 21148602
[TBL] [Abstract][Full Text] [Related]
18. Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN).
Watanabe R; Watanabe H; Sotozono C; Kokaze A; Iijima M
Eur J Dermatol; 2011; 21(6):889-94. PubMed ID: 21873140
[TBL] [Abstract][Full Text] [Related]
19. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases.
Abe R
J Dermatol Sci; 2008 Dec; 52(3):151-9. PubMed ID: 18657400
[TBL] [Abstract][Full Text] [Related]
20. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
Chung WH; Hung SI
Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]